CCP
CCCC icon

Clough Capital Partners’s C4 Therapeutics CCCC Stock Holding History

Clough Capital Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-356,181
Closed -$8.64M – 87
2022
Q1 		$8.64M Buy
356,181
+100,500
+39% +$2.44M 0.66% 53
2021
Q4 		$8.23M Sell
255,681
-91,819
-26% -$3.63M 0.55% 55
2021
Q3 		$15.5M Buy
347,500
+221,900
+177% +$9.5M 0.94% 44
2021
Q2 		$4.75M Buy
+125,600
New +$4.5M 0.26% 78

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Clough Capital Partners's CCCC Position: Q2 2022 in Review

Clough Capital Partners sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 356,181 shares — an estimated $8.64M sold.

Clough Capital Partners first reported a position in CCCC in Q2 2021 and held it in 4 quarters. The position peaked at $15.5M in Q3 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • Clough Capital Partners reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Clough Capital Partners sold 356,181 C4 Therapeutics shares in Q2 2022, an estimated $8.64M.
  • Clough Capital Partners first reported a position in C4 Therapeutics in Q2 2021 and held it in 4 quarters.
  • Clough Capital Partners's C4 Therapeutics position peaked at $15.5M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on Clough Capital Partners's 13F filing for Q2 2022, filed 16 Aug 2022.